Brief: Lisata Therapeutics Report First Patient Treated in Cholangiocarcinoma Cohort Of The BOLSTER Trial Of LSTA1
24/10/2023 14:14
Oct 24 (Reuters) - Lisata Therapeutics Inc LSTA.O :
* LISATA THERAPEUTICS ANNOUNCES FIRST PATIENT TREATED IN THE
CHOLANGIOCARCINOMA COHORT OF THE BOLSTER TRIAL OF LSTA1, A NOVEL
TUMOR-TARGETING AND PENETRATING PEPTIDE
* LISATA THERAPEUTICS INC - TOTAL TRIAL ENROLLMENT OF 120
PATIENTS
IS EXPECTED TO BE COMPLETED IN SECOND HALF OF 2024
Source text for Eikon: ID:nGNXcdmvK3
Further company coverage: LSTA.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Lisata Therapeutics
See all newsBrief: Lisata Therapeutics - Amends Merger Offer Price To $4 Per Share Plus CVR
Brief: Lisata Therapeutics Enters Into Definitive Agreement To Be Acquired By Kuva Labs, Inc.
U.S. STOCKS ON THE MOVE-Oklo, AMD, Lam Research
U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies
Lisata jumps as Kuva Labs strikes acquisition deal